Description
Description
Product Description:
Wedica is a once-weekly dipeptidyl peptidase-IV (DPP-4) inhibitor. It controls blood glucose levels by selectively and continually inhibiting DPP-4, an enzyme that causes the inactivation of glucagon-like peptide-1 and glucagon-dependent insulinotropic polypeptide, incretin hormones* that play an important role in blood glucose regulation. The inhibition of DPP-4 increases insulin secretion depending on blood glucose concentration, thereby controlling blood glucose levels. Wedica is available in tablet form for oral administration.
Product Features:
- Once Weekly Dose.
- Lesser hypoglycemic events.
- 4 and 12-fold more potent than Alogliptin and Sitagliptin.
| Product Name | : Wedica |
| Generic Name | : Trelagliptin Succinate |
| Formulation | : Tablet |
| Available size | : 2×10 ’s and 2×8’s |
| Strengths | : 50mg and 100mg |
Reviews
There are no reviews yet.